## David J Feola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7721468/publications.pdf

Version: 2024-02-01

315357 471061 1,563 40 17 38 citations h-index g-index papers 41 41 41 2283 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria. Annals of Pharmacotherapy, 1999, 33, 960-967.	0.9	492
2	Azithromycin alters macrophage phenotype. Journal of Antimicrobial Chemotherapy, 2008, 61, 554-560.	1.3	160
3	Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-κB Signaling Pathways. Journal of Immunology, 2019, 203, 1021-1030.	0.4	85
4	Azithromycin Alters Macrophage Phenotype and Pulmonary Compartmentalization during Lung Infection with Pseudomonas. Antimicrobial Agents and Chemotherapy, 2010, 54, 2437-2447.	1.4	81
5	Phytosterols differentially influence ABC transporter expression, cholesterol efflux and inflammatory cytokine secretion in macrophage foam cells. Journal of Nutritional Biochemistry, 2011, 22, 777-783.	1.9	76
6	Azithromycin drives alternative macrophage activation and improves recovery and tissue sparing in contusion spinal cord injury. Journal of Neuroinflammation, 2015, 12, 218.	3.1	76
7	Pathogenesis of Bronchopulmonary Dysplasia. Respiration, 2010, 79, 425-436.	1.2	73
8	Characterization of macrophage activation states in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 314-322.	0.3	61
9	Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. Journal of Thrombosis and Thrombolysis, 2013, 35, 147-154.	1.0	55
10	Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: Potential therapeutic targets in ischemic heart disease. PLoS ONE, 2018, 13, e0200474.	1.1	39
11	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. Frontiers in Immunology, 2021, 12, 574425.	2.2	38
12	Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatric Pulmonology, 2010, 45, 1145-1148.	1.0	36
13	B Lymphocytes Are Required during the Early Priming of CD4+ T Cells for Clearance of <i>Pneumocystis</i> Infection in Mice. Journal of Immunology, 2015, 195, 611-620.	0.4	36
14	Aerosolized vancomycin for the treatment of MRSA after lung transplantation. Respirology, 2010, 15, 184-186.	1.3	31
15	Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 164-171.	0.3	31
16	Linezolid Decreases Susceptibility to Secondary Bacterial Pneumonia Postinfluenza Infection in Mice Through its Effects on IFN-13. Journal of Immunology, 2013, 191, 1792-1799.	0.4	19
17	Metronidazole-Induced Pancreatitis in a Patient with Recurrent Vaginal Trichomoniasis. Pharmacotherapy, 2002, 22, 1508-1510.	1.2	18
18	Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing Enterobacter cloacae. Diagnostic Microbiology and Infectious Disease, 2018, 92, 262-266.	0.8	17

#	Article	IF	CITATIONS
19	Pulmonary function outcomes in bronchopulmonary dysplasia through childhood and into adulthood: implications for primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2011, 20, 128-133.	2.5	16
20	Arginase 1 Insufficiency Precipitates Amyloid- $\hat{l}^2$ Deposition and Hastens Behavioral Impairment in a Mouse Model of Amyloidosis. Frontiers in Immunology, 2020, 11, 582998.	2.2	15
21	Pneumocystis infection alters the activation state of pulmonary macrophages. Immunobiology, 2017, 222, 188-197.	0.8	14
22	Mucoid <i>Inquilinus limosus </i> in a young adult with cystic fibrosis. Pediatric Pulmonology, 2009, 44, 619-621.	1.0	12
23	Agents that increase AAM differentiation blunt RSV-mediated lung pathology. Journal of Leukocyte Biology, 2014, 96, 951-955.	1.5	12
24	Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2013, 68, 840-851.	1.3	11
25	Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction. Scientific Reports, 2020, 10, 16596.	1.6	10
26	Effect of the meropenem MIC on the killing activity of meropenem and polymyxin B in combination against KPC-producing Klebsiella pneumoniae. Journal of Antibiotics, 2017, 70, 974-978.	1.0	8
27	Myeloid Arginase 1 Insufficiency Exacerbates Amyloid-β Associated Neurodegenerative Pathways and Glial Signatures in a Mouse Model of Alzheimer's Disease: A Targeted Transcriptome Analysis. Frontiers in Immunology, 2021, 12, 628156.	2.2	6
28	Airway dehiscence after lung transplantation in a patient with cystic fibrosis. Respiratory Care, 2010, 55, 1746-50.	0.8	6
29	Delivering macrolide antibiotics to heal a broken heart – And other inflammatory conditions. Advanced Drug Delivery Reviews, 2022, 184, 114252.	6.6	5
30	Zidovudine plus sulfamethoxazole–trimethoprim adversely affects B lymphocyte maturation in bone marrow of normal mice. International Immunopharmacology, 2005, 5, 1881-1894.	1.7	4
31	Combination Exposure to Zidovudine plus Sulfamethoxazole-Trimethoprim Diminishes B-Lymphocyte Immune Responses to Pneumocystis murina Infection in Healthy Mice. Vaccine Journal, 2006, 13, 193-201.	3.2	4
32	Eradication of <i>Pseudomonas aeruginosa </i> in an adult patient with cystic fibrosis. American Journal of Health-System Pharmacy, 2011, 68, 319-322.	0.5	3
33	Myeloid arginase-1 controls excessive inflammation and modulates T cell responses in Pseudomonas aeruginosa pneumonia. Immunobiology, 2021, 226, 152034.	0.8	3
34	Development of Guiding Principles for a New Era in Graduate Education. American Journal of Pharmaceutical Education, 2019, 83, 7422.	0.7	3
35	Appropriateness of Term Limits for Administrative Appointments in Pharmacy Programs. American Journal of Pharmaceutical Education, 2020, 84, 7462.	0.7	3
36	Azithromycin and Major Adverse Kidney Events in Critically Ill Patients With Sepsis-Associated Acute Kidney Injury. Shock, 2022, 57, 479-485.	1.0	2

#	Article	IF	CITATIONS
37	Bias of the Immune Response to Pneumocystis murina Does Not Alter the Ability of Neonatal Mice to Clear the Infection. Journal of Fungi (Basel, Switzerland), 2021, 7, 827.	1.5	1
38	Lessons Learned From the COVID-19 Pandemic and the Implications for Pharmaceutical Graduate Education and Research. Advances in Medical Education, Research, and Ethics, 2022, , 324-345.	0.1	0
39	1410: AZITHROMYCIN AND MAJOR ADVERSE KIDNEY EVENTS IN CRITICALLY ILL PATIENTS WITH SEPSIS-ASSOCIATED AKI. Critical Care Medicine, 2022, 50, 707-707.	0.4	O
40	Optimization and Characterization of a Liposomal Azithromycin Formulation for Alternative Macrophage Activation. Frontiers in Drug Delivery, 0, 2, .	0.4	O